Skip to main content
Smart Investors Daily
PU

NASDAQ · PULM

Pulmatrix, Inc.

Healthcare · Biotechnology

$1.33

Down-$0.24 (-17.67%)

Updated Nov 4, 2026, 6:37 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.43M
P/E ratio
-2.32
Dividend yield
0.00%
52-week range
$1.16 – $2.49
Volume
56.14K
Avg. volume
11.96K

Price performance · PULM

PULM price history

1M range · 0 trading sessions · Daily adjusted prices

PULM does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest PULM news

The latest Smart Investors Daily articles mentioning PULM.

PULM research

Overview

Company profile and research snapshot.

Company profile

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PULM recent ratings
DateFirmRatingTarget
Aug 15, 2023HC Wainwright & Co.Buy—
May 15, 2023HC Wainwright & Co.Buy—
Feb 7, 2023HC Wainwright & Co.Buy—
Mar 30, 2022HC Wainwright & Co.Buy—
Apr 13, 2021HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse

In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)“Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and nightNew “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far h

Yahoo · Sep 22, 2026

Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicineEos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesityEos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing first-in-class mitochondrial-tar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.